|
Comparison of Intravenous Lignocaine and Dexmedetomidine for the Prevention Of Propofol Injection Pain
|
|
| Author:
|
AMOL SINGAM, AKOIJAM NIKHIL SINGH, Y.U. CHITRIV
|
| Abstract:
|
Background- Pain following administration of intravenous propofol is a frequent complication with incidence varying between 28-90% of adults. Numerous techniques have been applied and tested to decrease the severity of pain. Intravenous lignocaine is the most widely used technique to alleviate the pain following propofol administration. Dexmedetomidine is an immensely particular alpha 2 receptor agonist which has been shown to have peripheral anti-nociceptive properties by previous studies with additional sedative, anxiolytic and anti-hypertensive properties. The purpose of this study is to observe if injection dexmedetomidine is equal to or more efficacious in alleviating the pain following intravenous propofol administration.
Aim-To relate the effectiveness and infallibility of intravenous lignocaine and dexmedetomidine in the prevention of pain following propofol administration in patients posted for elective surgical procedures under general anaesthesia.
Materials and methods- A randomised, prospective, double blind study will be carried out in which 200 patients with ASA class 1 or 2 of either sex, aged between 18 – 70 years posted for elective surgical procedures under general anaesthesia using propofol as the agent for induction will be selected. These patients will be allotted randomly into two groups of 100 each using random number sampling generated by a computer and allocation of same sealed envelope technique to receive the study drugs after ethical approval. Group 1 will be administered intravenous lignocaine 0.2 mg/kg and group 2 will be administered intravenous dexmedetomidine 0.5 mcg/kg, 1 minute prior to injection propofol 2mg/kg body weight. Pain after propofol injection will be assessed in each patient using the McCrirrick and Hunter scale.
Expected results- No significant difference is anticipated in the demographic characteristics of the two study drugs. In group 1 receiving lignocaine 0.2mg/kg iv, 80% of the patients are anticipated to have no pain, 18% to have moderate pain whereas the rest of the 2% to have severe pain. In group 2 receiving dexmedetomidine 0.5mcg/kg iv, 63% of the patients are expected to experience no pain, 34% are expected to have moderate pain whereas 3% are expected to have severe pain. The occurrence of nausea, vomiting and hypotension might be more common in group 2 but would probably be clinically non-significant.
|
| Keyword:
|
General anaesthesia, pain.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2019.11.04.507
|
| Download:
|
Request For Article
|
|
|